The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...

A new Phase 2 clinical study is now enrolling adults with moderate to severe asthma to evaluate the safety and efficacy of Brenipatide, an investigational, once-weekly subcutaneous injection designed ...

Eswatini joined a handful of countries to officially roll out ‌new HIV prevention drug lenacapavir on Wednesday, announcing ...

Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...

KT501 is engineered to target a broad spectrum of B-cell populations, including plasma cells, by simultaneously binding to CD19 and BCMA. Unlike traditional B-cell therapies, KT501 is designed to ...

USD 8.7 Billion; 2032 Projected Market Size: USD 11.9 Billion; CAGR (2025–2032): 4.57%; Heparin Market forecast accounts for ...

The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP. She also explained how the ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based platform offers a new route to deliver insulin orally and may be applicable to ...

Alkem Laboratories is all set to launch a semaglutide injection under the brand names Semasize, Obesema and Hepaglide priced ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...